Assembly Biosciences

Assembly Bio has exercised the option to participate in 40% of US development costs and profits for the helicase-primase inhibitor program against the herpes simplex virus. Gilead remains responsible for clinical development and commercialization; Assembly is entitled to up to $280 million in milestones plus tiered royalties outside the US, with potential to increase payments to up to $330 million. GS-1179 is expected to enter a Phase 2 study by the end of 2026, and Assembly will receive a $75 million payment from Gilead in Q4 2026; existing cash is expected to be sufficient through 2029. » Plus sur de.investing.com

Assembly Biosciences has exercised its option and will receive 40% of the U.S. profit share in the helicase-primase inhibitor program against herpes being developed in collaboration with Gilead. Gilead remains responsible for clinical development and commercialization; the candidates are GS-1179 and GS-5366. Assembly is entitled to milestone payments of up to $280 million and tiered royalties outside the U.S.; exit or conversion rights could adjust these payments up to $330 million. GS-1179 is expected to enter a phase 2 study by the end of 2026, and Assembly expects to be funded through 2029 (including a $75 million fee in Q4 2026). » Plus sur de.investing.com

Assembly Biosciences completed a guaranteed capital increase, grossing about $115 million. The company sold 3,924,624 common shares at $26.50 each, including 566,040 additional shares from the overallotment option, and one investor purchased pre-funded warrants for up to 415,000 shares at $26.499 per warrant. The stock traded at $28.75 after the placement. Assembly intends to use the net proceeds to finance the clinical development of its pipeline candidates and for general corporate purposes; analysts have price targets between $40 and $62. » Plus sur de.investing.com